Dr. Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.
Previously, Dr. Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains an Operating Partner.
From 2004-2006, Dr. Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology.
Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree from Princeton University.
Dr. David Bonita, M.D., has served on the board of directors since September 2013.
Dr. Bonita is currently a Private Equity Partner at OrbiMed, where he serves on the boards of Clementia, Tricida, ViewRay, SI Bone, Acutus Medical Inc., Cryterion, Kyn Therapeutics, Prelude Therapeutics Inc., and Keystone Heart.
He previously served on the board of Enobia, Ambit Biosciences and CardiAQ. Prior to joining OrbiMed, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS. He has published several scientific articles in peer-reviewed journals based on research performed at the Harvard Medical School.
Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Mr. Steve Elms has served on the board of directors since July 2013.
Mr. Elms is currently a Managing Partner at Aisling Capital, a leading private equity fund investing in life science companies, and serves on the board of a number of public and private life sciences companies.
Previously, Mr. Elms was a senior member of the Life Sciences Investment Banking Group of Hambrecht & Quist and was involved in over 60 financing and M&A transactions, which helped clients raise in excess of $3.3 billion in capital. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories.
Mr. Elms received an M.B.A. from the Kellogg Graduate School of Management at Northwestern University, and a B.A. in Human Biology from Stanford University.
Dr. Keith T. Flaherty, M.D., has served as SAB Chair since company inception, and sits on the board of directors.
Dr. Flaherty is currently Director of Clinical Research and the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School.
Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certification in these specialties.
He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree from Yale University.
Mr. Avi Z. Naider has served on the board of directors since September 2013.
Mr. Naider is currently Chairman and CEO of ACES Risk Management Corp.
Mr. Naider is a successful entrepreneur who has founded and managed companies in various sectors, including internet advertising and mortgage industry software. He previously worked in private equity and for the Boston Consulting Group.
Mr. Naider received his A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University, where he graduated Phi Beta Kappa.
Dr. Lori A. Kunkel, M.D., has served on the board of directors since October 2014.
Dr. Kunkel served as Acting Chief Medical Officer for Loxo Oncology from October 2013 to October 2014.
As principal of LAK 505, LLC, she is a clinical/regulatory strategic advisor to public and private biotech companies in the San Francisco, San Diego, New York and Boston areas. She currently serves on the board of directors of Curis, Inc, Tocagen and Maverick Therapeutics and is a clinical advisor to Amphvena, Atreca and Verastem. Dr Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech.
Prior to joining the international biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.
She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties.
Alan Fuhrman has served on our board of directors since January 2015.
Mr. Fuhrman currently serves as CFO of Mirna Therapeutics (Nasdaq:MIRN) an oncology drug development company. He was CFO of Ambit Biosciences from October 2010 until its sale to Daiichi Sankyo in November 2014.
Prior to this role, he served as CFO of Naviscan, Inc., a privately-held medical imaging company from November 2008 until September 2010, and as CFO of Sonus Pharmaceuticals from September 2004 until August of 2008. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers & Lybrand.
Mr. Fuhrman received B.S. degrees in both business administration and agricultural economics from Montana State University.
Tim Mayleben has served on the board of directors since July 2015.
Mr. Mayleben is currently President and Chief Executive Officer at Esperion Therapeutics and has been a member of the board of directors since 2010.
Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo Pharma, Lycera Corporation, Marinus Pharmaceuticals and the Wolverine Venture Fund.
Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.
Dr. Steve D. Harr, M.D., joined the board of directors in November 2016.
Dr. Harr is currently the chief financial officer and head of corporate development at Juno Therapeutics, a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies.
Previously, Dr. Harr was managing director and head of biotechnology investment banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research.
Dr. Harr received a B.A. in economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. Dr. Harr was a resident in internal medicine at the University of California, San Francisco.